Andrew Hantel and Lauren Merz
Nov 20, 2025, 14:05
Andrew Hantel and Lauren Merz Had an Important Conversation About Appropriate Care
American Society of Hematology shared a post on LinkedIn:
“The Duffy-null phenotype is common among individuals of African, Middle Eastern, and North African ancestry, yet often misunderstood — leading to unnecessary procedures, inappropriate dose modifications, and exclusion from potentially life-saving therapies.
Join experts Drs. Andrew Hantel and Lauren Merz for an important conversation about appropriate care. Learn how Duffy-null affects absolute neutrophil counts (ANCs), clinical trial eligibility, and treatment decisions, including:
- How standard ANC cutoffs can disadvantage patients
- Implications for chemotherapy, immunosuppressive drugs, and clozapine
- The intersection of Duffy-null with recent updates to CTC AE grading
Listen now here.”
Read more here.
Stay informed with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH